Spatial Domain (Tier 1)
351-400 of 2,070
Download spatial tables
Spatial Domain (Tier 1)
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__175_C6,12 | Lung | Primary cancer | 3,479 | Tumor/Malignant | 69.8% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__175_C6,13 | Lung | Primary cancer | 4,420 | Tumor/Malignant | 42.9% | 0.90 | 0.36 |
| NSCLC_38242124__IMC__175_C6,14 | Lung | Primary cancer | 2,111 | Tumor/Malignant | 45.4% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__175_C6,15 | Lung | Primary cancer | 1,193 | Stromal | 38.3% | 0.79 | 0.48 |
| NSCLC_38242124__IMC__175_C6,16 | Lung | Primary cancer | 6,448 | Immune | 98.2% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__175_C6,2 | Lung | Primary cancer | 3,632 | Tumor/Malignant | 63.6% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__175_C6,3 | Lung | Primary cancer | 3,094 | Tumor/Malignant | 34.6% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__175_C6,4 | Lung | Primary cancer | 2,780 | Stromal | 40.9% | 0.53 | 0.83 |
| NSCLC_38242124__IMC__175_C6,5 | Lung | Primary cancer | 1,512 | Tumor/Malignant | 58.9% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__175_C6,6 | Lung | Primary cancer | 3,952 | Tumor/Malignant | 61.0% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_C6,7 | Lung | Primary cancer | 2,958 | Other | 27.1% | 0.47 | 0.88 |
| NSCLC_38242124__IMC__175_C6,8 | Lung | Primary cancer | 3,105 | Tumor/Malignant | 80.2% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__175_C6,9 | Lung | Primary cancer | 2,279 | Tumor/Malignant | 34.9% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__175_C7,1 | Lung | Primary cancer | 3,158 | Tumor/Malignant | 41.9% | 0.94 | 0.24 |
| NSCLC_38242124__IMC__175_C7,10 | Lung | Primary cancer | 2,719 | Tumor/Malignant | 42.4% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__175_C7,11 | Lung | Primary cancer | 3,325 | Tumor/Malignant | 34.6% | 0.57 | 0.81 |
| NSCLC_38242124__IMC__175_C7,12 | Lung | Primary cancer | 3,230 | Tumor/Malignant | 66.3% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__175_C7,13 | Lung | Primary cancer | 3,467 | Tumor/Malignant | 32.3% | 0.48 | 0.79 |
| NSCLC_38242124__IMC__175_C7,14 | Lung | Primary cancer | 1,598 | Stromal | 44.8% | 0.99 | 0.09 |
| NSCLC_38242124__IMC__175_C7,15 | Lung | Primary cancer | 2,553 | Tumor/Malignant | 28.7% | 0.43 | 0.89 |
| NSCLC_38242124__IMC__175_C7,16 | Lung | Primary cancer | 5,544 | Immune | 78.1% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__175_C7,2 | Lung | Primary cancer | 3,873 | Tumor/Malignant | 66.8% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__175_C7,3 | Lung | Primary cancer | 2,937 | Tumor/Malignant | 57.3% | 0.92 | 0.27 |
| NSCLC_38242124__IMC__175_C7,4 | Lung | Primary cancer | 2,526 | Tumor/Malignant | 57.6% | 0.93 | 0.24 |
| NSCLC_38242124__IMC__175_C7,5 | Lung | Primary cancer | 2,528 | Stromal | 32.7% | 0.90 | 0.33 |
| NSCLC_38242124__IMC__175_C7,6 | Lung | Primary cancer | 2,883 | Tumor/Malignant | 73.8% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__175_C7,7 | Lung | Primary cancer | 3,570 | Tumor/Malignant | 34.8% | 0.93 | 0.25 |
| NSCLC_38242124__IMC__175_C7,8 | Lung | Primary cancer | 3,179 | Tumor/Malignant | 55.7% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__175_C7,9 | Lung | Primary cancer | 3,931 | Stromal | 28.8% | 0.36 | 1.02 |
| NSCLC_38242124__IMC__175_C8,1 | Lung | Primary cancer | 1,215 | Tumor/Malignant | 39.3% | 0.90 | 0.36 |
| NSCLC_38242124__IMC__175_C8,10 | Lung | Primary cancer | 2,719 | Tumor/Malignant | 40.1% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__175_C8,11 | Lung | Primary cancer | 3,084 | Stromal | 34.4% | 0.90 | 0.31 |
| NSCLC_38242124__IMC__175_C8,12 | Lung | Primary cancer | 3,194 | Tumor/Malignant | 31.7% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__175_C8,13 | Lung | Primary cancer | 1,487 | Stromal | 32.3% | 0.37 | 1.02 |
| NSCLC_38242124__IMC__175_C8,14 | Lung | Primary cancer | 1,942 | Stromal | 55.2% | 0.78 | 0.45 |
| NSCLC_38242124__IMC__175_C8,15 | Lung | Primary cancer | 3,196 | Tumor/Malignant | 26.9% | 0.47 | 0.93 |
| NSCLC_38242124__IMC__175_C8,16 | Lung | Primary cancer | 4,858 | Immune | 81.0% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_C8,2 | Lung | Primary cancer | 4,357 | Tumor/Malignant | 62.1% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__175_C8,3 | Lung | Primary cancer | 5,989 | Immune | 66.1% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__175_C8,4 | Lung | Primary cancer | 1,743 | Tumor/Malignant | 48.8% | 0.93 | 0.20 |
| NSCLC_38242124__IMC__175_C8,5 | Lung | Primary cancer | 2,977 | Stromal | 42.7% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__175_C8,6 | Lung | Primary cancer | 2,712 | Tumor/Malignant | 76.5% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__175_C8,7 | Lung | Primary cancer | 4,293 | Other | 30.3% | 0.87 | 0.33 |
| NSCLC_38242124__IMC__175_C8,8 | Lung | Primary cancer | 3,076 | Tumor/Malignant | 31.9% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__175_C8,9 | Lung | Primary cancer | 2,964 | Tumor/Malignant | 31.5% | 0.59 | 0.85 |
| NSCLC_38242124__IMC__176_A1,1 | Lung | Primary cancer | 4,438 | Tumor/Malignant | 26.8% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__176_A1,10 | Lung | Primary cancer | 3,169 | Tumor/Malignant | 65.3% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__176_A1,11 | Lung | Primary cancer | 5,193 | Immune | 43.7% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__176_A1,12 | Lung | Primary cancer | 2,620 | Tumor/Malignant | 62.3% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__176_A1,13 | Lung | Primary cancer | 2,443 | Tumor/Malignant | 41.8% | 0.97 | 0.19 |